Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy Skip to content The CRC Digest ◆ TRIAL DATA Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy — Journal of Clinical Oncology . This blood-based test could help doctors identify which patients are responding to treatment without waiting for scans. What this means If you have a KRAS G12C
ctDNA clearance as early biomarker in KRAS G12C colorectal cancer Skip to content The CRC Digest ctDNA clearance as early biomarker in KRAS G12C colorectal cancer Phase 3 CodeBreaK 300 results link circulating tumor DNA clearance to efficacy and prognosis with sotorasib plus panitumumab. (JCO) This content is informational only and does not constitute medical advice. Always consult your oncologist
KRAS G12D-targeted therapy tested in preclinical models Skip to content The CRC Digest KRAS G12D-targeted therapy tested in preclinical models A nanomedicine delivering a KRAS G12D inhibitor showed promise in laboratory models of metastatic colorectal cancer. (Journal of Controlled Release) This content is informational only and does not constitute medical advice. Always consult your oncologist or care
CRC Research Finding Skip to content The CRC Digest ◇ Experimental nanomedicine targets KRAS G12D mutation in metastatic colorectal cancer Preclinical research describes a macrophage-hitchhiking delivery system combining gemcitabine and a KRAS G12D inhibitor that improved drug delivery to lung metastases and triggered immune responses in colorectal cancer models. (Journal of Controlled Release) This